The IASLC lung cancer staging project: Proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer

被引:423
作者
Rusch, Valerie W.
Crowley, John
Giroux, Dorothy J.
Goldstraw, Peter
Im, Jung-Gi
Tsuboi, Masahiro
Tsuchiya, Ryosuke
Vansteenkiste, Johan
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Thorac Serv, New York, NY 10021 USA
[2] Canc Res & Biostat, Seattle, WA USA
[3] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[4] Tokyo Med Univ, Tokyo, Japan
[5] Natl Canc Ctr, Tokyo 104, Japan
[6] Leuven Lung Canc Grp, Louvain, Belgium
[7] Royal Brompton Hosp, London SW3 6LY, England
关键词
lung cancer staging; Nodal descriptors;
D O I
10.1097/JTO.0b013e31807ec803
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Accurate staging of lymph node involvement is a critical aspect of the initial management of nonmetastatic non-small cell lung cancer (NSCLC). We sought to determine whether the current N descriptors should be maintained or revised for the next edition of the international lung cancer staging system. Methods: A retrospective international lung cancer database was developed and analyzed. Anatomical location of lymph node involvement was defined by the Naruke (for Japanese data) and American Thoracic Society (for non-Japanese data) nodal maps. Survival was calculated by the Kaplan-Meier method, and prognostic groups were assessed by Cox regression analysis. Results: Current NO to N3 descriptors defined distinct prognostic groups for both clinical and pathologic staging. Exploratory analyses indicated that lymph node stations could be grouped together into six "zones": peripheral or hilar for N1, and upper or lower mediastinal, aortopulmonary, and subcarinal for N2 nodes. Among patients undergoing resection without induction therapy, there were three distinct prognostic groups: single-zone N1, multiple-zone NI or single N2, and multiple-zone N2 disease. Nevertheless, there were insufficient data to determine whether the N descriptors should be subdivided (e.g., N1a, Nib, N2a, N2b). Conclusions: Current N descriptors should be maintained in the NSCLC staging system. Prospective studies arc needed to validate p amalgamating lymph node stations into zones and subdividing N descriptors.
引用
收藏
页码:603 / 612
页数:10
相关论文
共 44 条
[11]   Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease [J].
Keller, SM ;
Vangel, MG ;
Wagner, H ;
Schiller, JH ;
Herskovic, A ;
Komaki, R ;
Marks, RS ;
Perry, MC ;
Livingston, RB ;
Johnson, DH .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2004, 128 (01) :130-137
[12]   PATTERNS OF MEDIASTINAL METASTASES IN BRONCHOGENIC-CARCINOMA [J].
LIBSHITZ, HI ;
MCKENNA, RJ ;
MOUNTAIN, CF .
CHEST, 1986, 90 (02) :229-232
[13]  
MAGGI G, 1990, INT SURG, V75, P17
[14]   Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis [J].
Marra, A ;
Hillejan, L ;
Zaboura, G ;
Fujimoto, T ;
Greschuchna, D ;
Stamatis, G .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2003, 125 (03) :543-553
[15]   SURVIVAL AFTER RESECTION OF STAGE-II NON-SMALL-CELL LUNG-CANCER [J].
MARTINI, N ;
BURT, ME ;
BAINS, MS ;
TODD, TRJ ;
MCCORMACK, PM ;
RUSCH, VW ;
GINSBERG, RJ ;
CHAMBERS, JS .
ANNALS OF THORACIC SURGERY, 1992, 54 (03) :460-466
[16]  
Martini N, 1995, Chest Surg Clin N Am, V5, P189
[17]  
MARTINI N, 1983, J THORAC CARDIOV SUR, V86, P646
[18]   RESULTS OF SURGICAL RESECTION IN PATIENTS WITH N2 NONSMALL CELL LUNG-CANCER [J].
MILLER, DL ;
MCMANUS, KG ;
ALLEN, MS ;
ILSTRUP, DM ;
DESCHAMPS, C ;
TRASTEK, VF ;
DALY, RC ;
PAIROLERO, PC .
ANNALS OF THORACIC SURGERY, 1994, 57 (05) :1095-1101
[19]   Skip metastases: analysis of their clinical significance and prognosis in the IIIA stage of non-small cell lung cancer [J].
Misthos, P ;
Sepsas, E ;
Athanassiadi, K ;
Kakaris, S ;
Skottis, I .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2004, 25 (04) :502-508
[20]   Revisions in the International System for Staging Lung Cancer [J].
Mountain, CF .
CHEST, 1997, 111 (06) :1710-1717